NeuroMetrix Announces Quell Fibromyalgia Pilot With Synovation Medical Group
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Synovation Medical Group will conduct an evaluation of Quell® Wearable Pain Relief Technology™ in fibromyalgia patients.
“Clinical research on innovative therapies is an integral part of what we do”
"We have seen both clinical data and positive reviews that suggest that Quell may be beneficial in reducing pain and improving the quality of life in people who suffer from fibromyalgia," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "This clinical evaluation will provide additional evidence for fibromyalgia patients and their healthcare providers who are considering Quell as a pain relief option."
"Clinical research on innovative therapies is an integral part of what we do," said Kunal Gogna, M.D., of Synovation Medical Group. "We are excited to test the Quell technology and potentially add it to our multidisciplinary approach to pain management.” Led by Mauro Zappaterra, M.D., Ph.D., Director of Clinical Research, and by Dr. Gogna, Synovation Medical Group supports the use of medical devices as viable alternatives to medication for the treatment of various chronic pain ailments.
About Synovation Medical Group
Synovation Medical Group offers top-quality care through an extensive network of doctors, surgeons and specialists in areas including pain management, physical medicine and rehabilitation, physical therapy and spine care. In 1990, Synovation Medical Group was founded by Dr. Clayton Varga who wanted to share his vision to serve patients and community as leaders in musculoskeletal medicine. Visit Synovation Medical Group for more information.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer